Viewpoints

Returnees and home-grown talent aim to make China a pharmaceutical powerhouse.

How does the latest agency task force report resonate for pharma and radio-frequency identification?

Industry must look at manufacturing as a competitive advantage, not just a way to get product out the door.

From RFID and pedigrees to PAT and process understanding, industry professionals are eying the growing gap between ambitious high-level guidance and current practice, and wondering how they can bridge this new space and keep in compliance with the untested rules.

A cleverly developed patent portfolio can block or minimize competition long past a patent's 20-year lifespan.

My audit host clearly knew and lied about the planned changes.

We can learn a lot about today's regulatory environment as a whole if we take it all in.

The creation in the Paris Region of a multidisciplinary Institute of Technology will bring together the best researchers in world, innovative SMEs and the research centres of large industrial groups.

I always suspected that our purchasing manager had agreed to this just to save money . . .

Predictable outcomes lead to greater manufacturing efficiency and speed time to value.

Does "personalized medicine" mean personalized treatment or personalized molecules, custom made for a patient's specific biology?

To fully optimize MS performance, corresponding enhancements are required in the other functional components of the integrated LC/MS platform.

China's State Food and Drug Administration prepares to strengthen the enforcement of good manufacturing practices.

Animal testing and accounting can both be hazardous.

At this year's BIO conference, US Health and Human Services Secretary Mike Leavitt predicted that over the coming decade, "Medicine will be transformed from an instinctive art of alleviating symptoms to a science of personalized healthcare." Is industry ready?

From the most frenetic conference season in recent memory, trying to distill perspective from mental snapshots of Interphex, Wisconsin, and BIO 2006.

The principle of free movement of goods entrenched in the European Treaty makes it difficult for anyone to stop trading of a product between member states

How can we improve trust in medicines bought in foreign countries? After all, they will have been manufactured to the same standards and specifications as the medicines back home.

Hubert J.P. Schoemaker and William T. McCormick. Perhaps we could have not a special day, but just a moment to remember what we owe and who we we owe it to.

Despite worries that industry is slow to adopt anticounterfeiting technologies, the 2006 Interphex program is rife with new methods for securing the supply chain.

Senior management must be the champions of change in companies that are struggling financially or organizationally.

Vitamin D and a sunny window shed som light on product stability.

No one is better than Europe when it comes to innovative products at the forefront of the industry

Once the brightest students are interested in bioprocessing, it is vital that they are prepared and inducted into industry.

Madness in March: lost ingredients, missed lot numbers, and a million-dollar photo.

FDA's 2007 budget request funds homeland security and pandemic preparedness by reducing support for the agency’s core mission.

Secondary sensors help protect feedback control systems from the effects of sensor drift.

The outcomes of complex chains of reactions are hard to predict. Hindsight being 20–20, I can tell you that implementing the prohibition of alcohol in the 1920s-which was intended to reduce corruption and social problems, but actually lead to a rise in organized crime-was a bad idea.

So could the online auction formula be extended to the pharmaceutical industry? It might be a great way to make some big savings.

FDA data indicate expenditure by pharmaceutical companies on R&D has doubled since 1996. Why is intensive research yielding so few patented inventions and so few new drugs?